Renew Biotechnologies

Renew Biotechnologies operates across biotechnology, health diagnostics, and product research, applying sequencing methods to clinical and translational questions. Its offerings include Wasatch BioLabs’ sequencing laboratory, Resonant’s neuron-associated cell-free DNA platform, and technologies for methylome profiling and RNA characterization. The company describes workflows using native-read and long-read sequencing, alongside specialized sample preparation, bioinformatics, and clinical laboratory capabilities. These features distinguish its stated approach: preserving biological signals such as DNA methylation and RNA features in relevant workflows, rather than relying on conversion or amplification steps that can alter those signals. Its work ranges from research and assay development to clinical testing and quality control, with applications that include neurodegeneration, fertility, infectious disease biomarkers, and RNA products. Mayo Clinic, Agilent, and Boston Heart Diagnostics are identified as partners, not competitors. Its stated focus is specialized sequencing-enabled diagnostics rather than a broad, general-purpose testing portfolio.

Founded in June 2022, Renew Biotechnologies has developed a portfolio spanning sequencing services and diagnostic platforms. The 2025 milestones include Wasatch BioLabs expanding its Oxford Nanopore assay portfolio on October 6 and Resonant receiving a DNA sequencing innovation award on November 7. In January 2026, the company’s Wasatch BioLabs subsidiary began supporting Path Fertility’s NOA Guide through assay development and clinical testing; in February, Renew partnered with Valinor Discovery on neurological disease modeling. A key organizational inflection point came in July 2026, when Wasatch BioLabs and Resonant were unified under the Renew brand. Subsequent milestones included peer-reviewed neurodegeneration biomarker research on August 7 and an October 1 collaboration to evaluate NeuroLens in multiple sclerosis and related diseases. These steps suggest a shift toward bringing service capabilities and disease-focused platforms together under one identity. The recorded employee-size band is 11–50, while one current position is listed; that discrepancy makes staffing trends difficult to infer.